SK Licenses 1ST-104 for Parkinson Disease
SK Biopharmaceuticals licensed exclusive global rights to 1ST-104, a preclinical oral Type 2 LRRK2 and c-Abl dual inhibitor from 1ST Biotherapeutics. The agreement is valued at up to $314.8 million, including $1.8 million upfront,…
